Two Sigma Advisers’s Enliven Therapeutics ELVN Stock Holding History

Two Sigma Advisers’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,425	Closed	-$105K	–	2629
2022 Q4	$105K	Buy	+6,425	New	+$103K	﹤0.01%	2290
2022 Q3	–	Sell	-45,700	Closed	-$223K	–	2597
2022 Q2	$223K	Sell	45,700 -25,300	-36%	-$124K	﹤0.01%	2244
2022 Q1	$534K	Buy	71,000 +6,550	+10%	+$43.2K	﹤0.01%	1958
2021 Q4	$580K	Sell	64,450 -700	-1%	-$9.18K	﹤0.01%	1847
2021 Q3	$1.06M	Buy	+65,150	New	+$1.35M	﹤0.01%	1590
2021 Q2	–	Sell	-4,125	Closed	-$139K	–	2510
2021 Q1	$139K	Buy	+4,125	New	+$210K	﹤0.01%	2404

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Two Sigma Advisers's ELVN Position: Q1 2023 in Review

Two Sigma Advisers sold out of Enliven Therapeutics (ELVN) in Q1 2023, closing a stake of 6,425 shares — an estimated $105K sold.

Two Sigma Advisers first reported a position in ELVN in Q1 2021 and held it in 6 quarters. The position peaked at $1.06M in Q3 2021. 45 funds tracked by Wall St. Rank hold ELVN as of Q1 2023.

Two Sigma Advisers reported no remaining Enliven Therapeutics position as of Q1 2023 after selling out during the quarter.
Two Sigma Advisers sold 6,425 Enliven Therapeutics shares in Q1 2023, an estimated $105K.
Two Sigma Advisers first reported a position in Enliven Therapeutics in Q1 2021 and held it in 6 quarters.
Two Sigma Advisers's Enliven Therapeutics position peaked at $1.06M in Q3 2021.
45 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2023.

Based on Two Sigma Advisers's 13F filing for Q1 2023, filed 15 May 2023.